Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MASPAC: MR-Guided Adaptive SBRT for Pain Control in mPDAC
NCT05114213Phase 2Terminated
- Sponsor
- Ludwig Maximilian University of Munich
- Start
- Dec 2021
- Primary completion
- Nov 2025
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by Ludwig Maximilian University of Munich. Primary endpoint: Mean cumulative pain index at 24 weeks. Started Dec 2021; status: terminated.
02
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05114213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05114213.